Business Context and Reporting Period
Company: Nektar Therapeutics (NKTR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Nektar is a clinical-stage biopharmaceutical company focused on immunotherapy. Its primary asset is rezpegaldesleukin (NKTR-358), an IL-2 receptor agonist for autoimmune diseases, alongside oncology candidate NKTR-255 and autoimmune candidate NKTR-0165. The company recently sold its manufacturing facility in Huntsville, Alabama, to Gannet BioChem in December 2024, transitioning to a contract manufacturing model.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $11,790 | $24,124 | $33,425 | $69,252 |
| Net Loss | $(35,522) | $(37,057) | $(127,997) | $(126,222) |
| Loss Per Share (Basic/Diluted) | $(1.87) | $(2.66) | $(8.14) | $(9.27) |
| Operating Cash Flow (9M) | $(143,552) | $(129,522) | — | — |
| Cash & Investments (Sep 30, 2025) | $270,208 | — | — | — |
| Total Liabilities | $216,261 | — | — | — |
Note: Revenue is primarily non-cash royalty revenue related to the sale of future royalties. Product sales were $0 in 2025 following the sale of the manufacturing facility.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 51% in Q3 2025 compared to Q3 2024, driven by a 100% drop in product sales (due to facility sale) and a 27% decrease in non-cash royalty revenue.
- Expense Reduction: Total operating costs and expenses decreased 26% in Q3 2025. Research and Development (R&D) expenses fell 22% to $27.3 million, and General and Administrative (G&A) expenses fell 15% to $16.1 million.
- Restructuring Costs: Restructuring and impairment charges were minimal in 2025 ($0.14M in Q3) compared to significant charges in 2024 ($14.3M for the nine months ended Sep 30, 2024), which included $8.3M in asset impairments.
- Equity Financing: In Q3 2025, the company raised approximately $141.5 million through a secondary offering ($107.2M) and At-The-Market (ATM) offerings ($34.3M), significantly bolstering liquidity.
- Reverse Stock Split: A 1-for-15 reverse stock split was effected on June 8, 2025. All share and per-share data have been retrospectively adjusted.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Clinical Progress: The Phase 2b REZOLVE-AD trial for rezpegaldesleukin in atopic dermatitis met its primary endpoint and key secondary endpoints. The company expects topline data for the Phase 2b REZOLVE-AA trial (alopecia areata) in December 2025.
- Liquidity: Management estimates sufficient cash and investments ($270.2 million as of Sep 30, 2025) to fund operations for at least the next 12 months.
- Future Expenses: R&D expenses for rezpegaldesleukin are expected to increase in full-year 2025 as the company prepares for Phase 3 trials. Expenses for NKTR-255 are expected to decrease following the completion of its Phase 2 study.
Risks and Contingencies
- Litigation: Ongoing litigation against Eli Lilly regarding the termination of their collaboration agreement. A jury trial was postponed due to the federal government shutdown; a status conference is scheduled for December 11, 2025.
- Regulatory & Clinical Risk: High risk of failure in clinical development. Rezpegaldesleukin is the company's primary asset; failure would significantly harm the business.
- Supply Chain: Post-facility sale, the company is dependent on Gannet BioChem for the supply of PEG reagents used in manufacturing.
- Capital Requirements: Continued substantial net losses are expected. Future capital needs may require dilutive equity financings or new collaborations.
Investor Verification Checklist
- Cash Runway: Verify the $270.2 million cash position against projected burn rates for Phase 3 rezpegaldesleukin trials.
- Revenue Quality: Confirm the non-cash nature of the majority of revenue (royalty amortization) and the cessation of product sales revenue.
- Litigation Status: Monitor the outcome of the Eli Lilly lawsuit and the rescheduled trial date following the December 2025 status conference.
- Clinical Data: Await the December 2025 topline data for the REZOLVE-AA (alopecia areata) trial to assess commercial potential.
- Equity Dilution: Review the impact of the recent secondary offering and ATM sales on shareholder ownership percentages.